摘要
目的探讨中低位直肠癌术前超分割放疗联合mFOLFOX6方案全身化疗的临床效果。方法选取本院2010年11月～2012年12月诊治的中低位直肠癌患者66例，随机分为两组，术前常规分割放疗联合mFOLFOX6方案全身化疗患者33例为对照组，术前超分割放疗联合mFOLFOX6方案全身化疗患者33例为观察组，比较两组患者治疗前后的肿瘤分期情况、手术切除率、保肛率、骨髓抑制及直肠反应分级情况。结果治疗后，两组患者肿瘤分期均明显改善；观察组肿瘤分期明显优于对照组，差异有统计学意义（P〈0．05）。两组患者的手术切除率、保肛率、骨髓抑制分级和直肠反应分级比较差异无统计学意义（P〉O．05）。结论术前超分割放疗联合mFOLFOX6方案全身化疗是治疗中低位直肠癌的有效方法，可明显改善患者的预后。
Objective To investigate clinical effect of preoperative hyperfractionated radiotherapy and mFOLFOX6 scheme chemotherapy in the treatment of mid-low rectal cancer.Methods 66 patients with mid-low rectal cancer were selected in our hospital from November 2010 to December 2012 were randomly divided into two groups.33 patients were treated with routine preoperative radiotherapy and mFOLFOX6 scheme chemotherapy as control group.33 patients were treated with preoperative hyperfractionated radiotherapy and mFOLFOX6 scheme chemotherapy as observation group.Tumor staging,operation excision rate,anal preservation rate,bone marrow suppression and rectal reaction classifi- cation in two groups before and after treatment were compared.Results After treatment,tumor staging of two groups was significantly improved,tumor staging of observation group was significantly better than that of control group,with statisti- cal difference（P〈0.05）.Operation excision rate,anal preservation rate,bone marrow suppression and rectal reaction classi- fication in two groups were compared,with no statistical difference （P〉0.05）.Conclusion Preoperative hyperfractionated radiotherapy and mFOLFOX6 scheme chemotherapy is effective method in the treatment of mid-low rectal cancer, which can significantly improve prognosis.
出处
《中国当代医药》
2014年第1期30-31,共2页
China Modern Medicine
